1 the first cell is essential for viral 2 clearance in a pre-exposure 3 prophylaxis model 4 Abstract Pre-exposure prophylaxis (PrEP) uses relatively weak HIV inhibition to reduce 12 transmission between individuals. Why this approach is successful is unclear. Here we derive and 13 experimentally validate a mathematical model for predicting infection clearance with PrEP based 14 on the measured effect of a drug on the HIV replication ratio and number of initial infected cells. 15 We tested the model by inhibiting low dose HIV infection with tenofovir, which reduces infection 16 frequency per cell, and atazanavir, which reduces the cellular burst size of viable virions. Both 17 drugs were at concentrations which allowed similar HIV replication. Reducing infection frequency 18 dramatically increased infection clearance, while reducing burst size did not. This indicates that 19 initial infection is vulnerable to inhibition before it infects the first cell, but not thereafter. Our 20 model explains why PrEP is potent at drug concentrations which are ineffective against established 21 infection, and provides a framework to test drug effectiveness for PrEP. 22 23 33
was shown to be effective in a non-human primate model of low dose infection, even when dosing 40 was intermittent (García-Lerma et al. (2008) ). In contrast to PrEP, TFV and FTC are only used in 41 combination with a highly potent ARV such as dolutegravir or efavirenz to suppress established 42 infection (https://aidsinfo.nih.gov/guidelines/html/1/adult -and-adolescent-arv/11/what-to-start) . 43 The majority of clinical studies have shown PrEP effectiveness in a variety of populations, Manuscript submitted to eLife the viral life cycle (http://aidsinfo.nih.gov/). Among the most commonly used are inhibitors of the 60 HIV proteins reverse transcriptase, integrase, and protease. Reverse transcriptase and integrase 61 inhibitors prevent the initial infection of the cell but do not interfere with viral production from 62 an already infected cell. Protease inhibitors do not interfere with cellular infection but reduce the 63 number of viable virions an infected cell produces by interfering with virion maturation, which 64 requires the HIV protease. Hence, the two mechanisms of inhibition involve either decreasing 65 HIV infection frequency or viral burst size (Delbrück (1945)) per infected cell. However, it has been 66 reported that protease inhibitors decrease infection frequency to some extent (Rabi et al. (2013) ). 67 The effect of decreasing infection frequency or burst size should be symmetrical. The number of 68 successful infections will be decreased if virions are prevented from infecting a cell by blocking their 69 ability to become a provirus capable of generating new virions. It will also be decreased by reducing -the probability that infection will be terminated as a consequence of the inhibitor -is unknown. 85 Here we modeled HIV infection as a function of the initial mean number of infected cells and 86 the replication ratio 0 , both of which we measured experimentally. We used two types of inhibition: 87 reduction of infection frequency mediated by TFV, and reduction of the burst size of viable virions 88 mediated by atazanavir (ATV), a drug belonging to the class of HIV protease inhibitors. We observed 89 that while both drugs reduced 0 to a similar extent at the concentrations used, only TFV, which 90 prevented successful infection of the first set of cells, was effective at clearing infection. 93 We first set out to model the effect of reducing infection frequency and burst size on the probability to clear infection ( ). We model the infection chain of HIV transmissions between cells by using a branching process (Athreya et al. (2004) ). We consider the initial stages of HIV infection, where host cells are not limiting in the number of cells that can be infected (Ribeiro et al. (2010) ; Nowak and May (2000) ). An infected cell produces a burst of virions. is on the order of 10 3 to 10 4 (Eckstein et al. (2001) ; Chen et al. (2007) ). The probability of one virion infecting the next cell is , the infection frequency. We note the maximum number of cells which can be infected per burst is . A key quantity is the product 0 = (Nowak and May (2000) ). 0 is approximately 10 in vivo (Ribeiro et al. (2010) ). Eventual infection clearance is certain for 0 ≤ 1. For 0 > 1, infection may still be cleared if, at any point in the infection chain, the number of infected cells is zero. Hence, we define the probability that infection is cleared as:
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Results
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Derivation of a model for infection clearance
where is the number of infected cells in the -th transmission step. 94 3 of 16
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We denote by the probability that infection starting from a single infected cell is cleared. In the 95 biologically relevant case where is large and is small, with 0 finite, we can calculate as (see 96 derivation in Materials and Methods):
Here, is the Lambert −function (Gradshteyn and Ryzhik (2014)), the inverse of the function 98 ( ) = . 99 As defined, is the probability that the infection originating in a single infected cell will be 100 cleared. We note that in the case where host cells are not limiting, as occurs in the initial stages of 101 infection, infection chains originating from individual infected cells are independent of each other. 102 Hence, given initial infected cells, 103 = .
(2)
We consider the initial number of infected cells as a random variable from a distribution ,
then becomes:
We now consider the effect of the antiretroviral drug mechanism on and . We note that ARVs 108 reduce either infection frequency or burst size . For drugs which reduce infection frequency, 109 → 1 , and for drugs which reduce viral burst size, → 2 , where 0 ≤ 1 , 2 ≤ 1. Given 0 = 110 and therefore 0 → 0 1 2 , the effects of the drug mechanisms are symmetrical on :
Hence, if the drugs decrease 0 to a similar extent, their effect on will also be similar. However, 112
given an initial transmission with cell-free virus, only the drug mechanism that decreases infection 113 frequency will reduce the mean initial number of infected cells . The mechanism which reduces 114 burst size will only affect the success of the next transmission cycle. Therefore, the probability to 115 clear infection with ARVs becomes:
Here is determined by Eq. (4). Given that is expected to be small, on the order of one 117 infected cell, the probability of clearance is expected to be very sensitive to the drug mechanism 118 which reduces infection frequency ( 1 ), provided the effect of the drug is present when initial infec-119 tion takes place. The drug mechanism which reduces burst size ( 2 ) misses this initial intervention 120 point.
121
To visualize the effects of decreasing 0 versus , we plotted Eq.
(3) for a range of parameter 122 values ( Figure 2A ). It can be observed that for 0 ≤ 1, infection terminates. At 0 ⪆ 1.5, infection is 123 not strongly sensitive to the exact 0 value. However at all 0 > 1 values, the probability of infection 124 clearance is very sensitive to , provided is small. This sensitivity is greatly reduced when ⪆ 2.
125
To examine the effects of drug mechanism, we plotted infection clearance according to Eq. (5) at 126 two conditions of 0 and relative to 1 and 2 ( Figure 2B ). In the first condition, 0 was sufficiently 127 small to be decreased below 1 by the drugs in the inhibition range used, while was large. In the We titrated TFV and ATV to obtain a similar effect on ongoing viral replication, which occurred at 148 60 M and 16 M of TFV and ATV respectively. We then infected cells in the presence of these drug 149 concentrations and measured infection over time to precisely measure 0 for each drug condition. 150 We initiated infection with the same dose of cell-free HIV for each infection condition. The number of infected cells at each time-point is normalized by the number of infected cells at day 2 and corrected for the dilution factor used in each infection cycle. 3 independent experiment were performed, with each point denoting the mean ± std of 3 experimental replicates per experiment. Infection in the absence of drug is shown as red circles, TFV as blue triangles, and ATV as green squares. (C) Effect of drug on . For each drug condition was measured 2 days after cell-free HIV infection and normalized by for no drug. Mean ± std of 3 independent experiments, where normalization was with in the absence of drug as measured in the same experiment. Raw numbers of infected cells averaged over all experiments were 1.3 10 4 ± 1.5 10 3 for no drug infection, 3.4 10 2 ± 1.3 10 2 for TFV and 1.1 10 4 ± 7.4 10 3 for ATV (mean ± std).
Manuscript submitted to eLife at a 1:2 ratio for infection conditions with drug. Proliferation of uninfected cells was sufficient to 155 maintain uninfected cell numbers, and infection was below 5 percent for both drug conditions 156 at all time-points, ensuring target cells were not limiting ( Figure 3A ). For the no drug condition, 157 the infection expanded much more rapidly. Therefore, the infected cell culture was passaged by 158 diluting the infected cells 1:100 every 2 days into uninfected cells. Infection was monitored over 8 159 days. Despite the use of the same HIV cell-free input dose, there were pronounced differences at 160 day 2 between TFV and ATV ( Figure 3A) . This time-point reflects the results of the initial cell-free 161 infection given an approximately 2 day viral cycle (Perelson et al. (1996) ). Cell-free infection was 162 strongly inhibited by TFV relative to no drug. In contrast, the effect of ATV on cell-free infection was 163 much weaker. After the day 2 time-point, infection expanded with similar dynamics for both drug 164 conditions, and much more rapidly when no drug was present. 165 We plotted the total number of infected cells, corrected for cells removed during passaging, 166 versus time ( Figure 3B ). We then calculated the effect of drug on 0 over a two day cycle (Table 1) .
167 0 values were calculated as 4.2 ± 0.73 for TFV and 3.2 ± 0.088 for ATV (mean ± std). 0 for infection 168 in the absence was 143 ± 15 in the cell line. We then measured the effect of the drugs on after 169 the first cycle of infection (day 0 to day 2), and compared the results to infection in the absence of 170 drug. in the presence of drug divided by for the no drug condition ( ) was 0.027 ± 0.014 for 171 TFV and 0.88 ± 0.16 for ATV, ( Figure 3C , Table 1 ). We then set out to investigate whether TFV and ATV could increase the probability of clearance Figure 4B ). 186 We did not experimentally observe clearance of infection in the absence of drug. In the presence 187 of TFV, clearance rose dramatically, with approximately three quarters of infections extinguished. In 188 contrast, only a minor increase of infection clearance was observed with ATV ( Figure 4C ). Clearance 189 with TFV was significantly higher relative to no drug and ATV, while ATV was not significantly different . Probability of infection clearance depends on drug mechanism. (A) Determination of . The number of infected cells was measured using flow cytometry as a function of cell-free HIV RNA copies for four virus stock dilutions yielding a number of infected cells above the limit of detection after one infection cycle. Data was then fit using linear regression to determine the input viral dose for 3 infected cells. Mean ± std of 5 independent experiments. Dotted line is limit of detection. Green arrow marks number of HIV RNA copies used in the experiments. (B) Representative flow cytometry plots after 8 days of infection with the input cell-free virus in the presence of of TFV or ATV and further 6 days amplification of the same infection in the absence of drug. Each plot represents one independently cultured replicate of the experiment. Uninfected samples are shown in the left column, and infection in the presence of TFV or ATV is shown in the middle and right column respectively. X-axis is GFP fluorescence, y-axis is autofluorescence. The fraction of infected cells corresponds to the cells within the area outlined in green or red, with green indicating background GFP signal level as determined from the uninfected samples, and red indicating above background signal. (C) as predicted by Eq. (5) (gray bars) based on the measured drug effects on 0 and , and as experimentally measured (red bars). Presence of infection was assayed in 26 (no drug) or 27 (TFV and ATV) cell-free virus infected cell cultures from 4 independent experiments. Observed was significantly higher than and ( < 10 −5 by bootstrap). and were not significantly different ( = 0.37 by bootstrap). 196 In this study we modeled and experimentally measured the clearance probability of initial HIV This may make achieving 0 ⪅ 1 more difficult than with therapy for established infection. Under 205 this set of conditions and in agreement with model predictions, only TFV, the inhibitor which was 206 able to act before the first cell was infected, was able to increase the probability of HIV clearance. 207 The prediction was based on two parameters which were readily measurable: is measured in 208 one infection cycle with cell-free virus. 0 is measured using multiple viral cycles, but consists 209 of relatively simple passaging of infection to ensure that uninfected target cells are not limiting. 210 Prediction does require the calculation of the the Lambert function. This can be done by a wide 211 range of algebra capable programs (in this study we used Matlab). 212 We show that the current PrEP approach utilizing drugs which target infection frequency is 213 in fact the correct choice. However, the quantitative model presented here has utility beyond 214 giving a rationale for what is already done. For example, ARVs with longer half-lives such as the 215 integrase inhibitor cabotegravir may become future treatment modalities both as ongoing therapy 216 and for PrEP (Andrews and Heneine (2015)). However, longer half-lives also result in the drug levels The model output using the measured values for and 0 resulted in predicted probabilities of 242 infection clearance which were higher than the experimentally observed clearance frequencies for 243 all conditions. We speculate that the reason is an underestimation of the input number of infected 244 cells . We measured one viral cycle after cell-free infection. If GFP expression in an infected cell 245 9 of 16
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Manuscript submitted to eLife was below threshold of detection at that time, the cell would be missed in the assay yet still amplify 246 infection. Despite this, the relative effectiveness of each drug mechanism was clearly predicted by Baltimore (2012)). Evidence for this is the emergence of drug resistance with monotherapy (Deeks 260 et al. (1997) ; Molla et al. (1996) ; Wei et al. (2002) ). The current study provides a different rationale 261 for why PrEP works best if the virus is inhibited before the first cellular infection, and enables a 262 generalized evaluation of drugs to screen for the best candidates for this intervention. Derivation of the mathematical model 324 The probability that one cell with a burst of virions will infect cells and not infect − cells is:
where id the infection probability per cell and = !∕ !( − )!. We define the generating 325 function for this probability distribution:
Using the binomial formula ∑ For > 1, the extinction probability of infection is given by the smallest root of ( ) = (Grimmett 328 and Stirzaker (2001)), that is:
In the biologically relevant case where is large and is small, with 0 finite, we approximate 330 the solution ( + 1 − ) = ln( +1− ) = ln(1+ ( −1)) ≃ ( −1) . Therefore, 331 = − 0 (1− ) .
The solution for to this equation is presented as Eq. (1 
